We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+35.19%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$336M
AUM Growth
+$28.4M
Cap. Flow
-$47.2M
Cap. Flow %
-14.05%
Top 10 Hldgs %
56.86%
Holding
90
New
10
Increased
16
Reduced
26
Closed
16

Top Buys

Rank Stock Value
1
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$4.4M
2
FLNA
Filana Therapeutics
FLNA
+$4.02M
3
VERO
Venus Concept
VERO
+$3.39M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$2.94M
5
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
+$2.73M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$22.2M
2
ARCT icon
Arcturus Therapeutics
ARCT
+$9.85M
3
FATE icon
Fate Therapeutics
FATE
+$6.46M
4
BEAT
BioTelemetry, Inc.
BEAT
+$2.89M
5
BPMC
Blueprint Medicines
BPMC
+$2.76M

Sector Composition

Rank Sector Weight
1 Healthcare 89.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASMB icon
76
Assembly Biosciences
ASMB
$529M
– –
-2,964
Closed -$585K
BCRX icon
77
BioCryst Pharmaceuticals
BCRX
$2.4B
– –
-749,051
Closed -$2.57M
CRDF icon
78
Cardiff Oncology
CRDF
$77.2M
– –
-5,000
Closed -$71K
DMAC icon
79
DiaMedica Therapeutics
DMAC
$364M
– –
-156,529
Closed -$664K
KALV
80
DELISTED
KalVista Pharmaceuticals
KALV
– –
-208,054
Closed -$2.62M
SPRO icon
81
Spero Therapeutics
SPRO
$73M
– –
-100,000
Closed -$1.12M
ZYME icon
82
Zymeworks
ZYME
$1.67B
– –
-9,950
Closed -$463K
ASLN
83
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
– –
-2,152
Closed -$164K
GMDA
84
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
– –
-140,000
Closed -$581K
SPPI
85
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
– –
-514,891
Closed -$2.1M
SIOX
86
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-171,083
Closed -$790K
CHMA
87
DELISTED
Chiasma, Inc. Common Stock
CHMA
– –
-153,208
Closed -$659K
IMMU
88
DELISTED
Immunomedics Inc
IMMU
– –
-260,905
Closed -$22.2M
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, DAFNA Capital Management held 90 positions worth $336M, up 9.2% from $308M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

DAFNA Capital Management withdrew a net $47.2M in Q4 2020, closing 16 positions and reducing 26 holdings. Its most notable exit was Immunomedics Inc, an estimated $22.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 83% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Filana Therapeutics worth $3.07M.

  • DAFNA Capital Management's largest Q4 2020 buy was Filana Therapeutics: 450,000 shares worth $3.07M.
  • DAFNA Capital Management added most to Lakefront Biotherapeutics American Depositary Shares in Q4 2020, an estimated $4.4M increase.
  • DAFNA Capital Management's biggest Q4 2020 reduction was Fate Therapeutics, cutting an estimated $6.46M.
  • DAFNA Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $22.2M.
  • DAFNA Capital Management's ten largest holdings make up 57% of its $336M portfolio in Q4 2020.
  • DAFNA Capital Management opened 10 new positions and closed 16 in Q4 2020.
  • DAFNA Capital Management's portfolio value rose 9.2% quarter-over-quarter to $336M.

Based on DAFNA Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.